title: In vitro pharmacologic profile of YM158, a new dual antagonist for LTD4 and TXA2 receptors.
abstract: YM158 (3-[(4-tert-butylthiazol-2-yl)methoxy]-5'-[3-(4-chlorobenzenesu lfonyl ) propyl]-2'-(1H-tetrazol-5-ylmethoxy)benzanilide monosodium salt monohydrate) antagonizes leukotriene (LT) D4 and thromboxane (TX) A2 receptors. Functional assays in vitro showed that YM158 exhibits competitive dual antagonism of LTD4 and TXA2 receptor-mediated contraction of isolated guinea pig tracheae, with pA2 values of about 8.87 and 8.81, respectively. Its antagonistic activity for the LTD4 receptor was approximately 6.5 times less potent than that of montelukast, and that for the TXA2 receptor was 2.5 times more potent than that of seratrodast. YM158 also inhibited PGD2- and PGF2alpha-induced tracheal contractions. YM158 showed no antagonism against LTC4-, histamine- or carbachol-induced contractions of guinea pig tracheae. Furthermore, YM158 antagonized the stable TXA2 analog U46619-induced aggregation of both guinea pig and human platelets and inhibited the LTD4-induced contraction of guinea pig ileum. From these results, YM158 appears to be a novel, selective dual antagonist for both LTD4 and TXA2 receptors.
authors.affiliation: Inflammation Research Pharmacology Laboratories, Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba-shi, Ibaraki, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Arakida
authors.forename: K
authors.initials: K
authors.lastname: Suwa
authors.forename: K
authors.initials: K
authors.lastname: Ohga
authors.forename: M
authors.initials: M
authors.lastname: Yokota
authors.forename: K
authors.initials: K
authors.lastname: Miyata
authors.forename: T
authors.initials: T
authors.lastname: Yamada
authors.forename: K
authors.initials: K
authors.lastname: Honda
mesh_terms: D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid / Q000494:pharmacology; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D015237:Dinoprost / Q000494:pharmacology; D006168:Guinea Pigs; D006801:Humans; D066298:In Vitro Techniques; D020024:Leukotriene Antagonists; D017998:Leukotriene D4 / Q000494:pharmacology; D008297:Male; D008565:Membrane Proteins; D009119:Muscle Contraction / Q000187:drug effects; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology; D015230:Prostaglandin D2 / Q000494:pharmacology; D018077:Receptors, Leukotriene; D017482:Receptors, Thromboxane / Q000037:antagonists & inhibitors*; D013777:Tetrazoles / Q000494:pharmacology*; D013844:Thiazoles / Q000494:pharmacology*; D014132:Trachea / Q000187:drug effects / Q000502:physiology
chemical_list: D020024:Leukotriene Antagonists; D008565:Membrane Proteins; D010975:Platelet Aggregation Inhibitors; D018077:Receptors, Leukotriene; D017482:Receptors, Thromboxane; D013777:Tetrazoles; D013844:Thiazoles; C115704:YM 158; D017998:Leukotriene D4; D019796:15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid; D002217:Carbachol; C412375:cysteinyl leukotriene receptor 2; D015237:Dinoprost; C083169:leukotriene D4 receptor; D015230:Prostaglandin D2